• Small Molecules
      • Discovery
    • Large Molecules
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers

Blogs

Choose from a variety of resources to get a better understanding of Syngene’s point of view, expertise or approach to drug discovery, development and manufacturing to ensure client success.

Solving problems with science: Gene to GMP-grade clinical supply in nine months
How Syngene’s proprietary data platform is safely and efficiently reducing the time taken to produce mAbs from gene to GMP-grade clinical supply by several months.
6th Sep, 2022
Minimizing environmental footprint the Syngene way
How Syngene is driving behavioural change in responsible use of natural resources while researching new technology and opportunities to improve its sustainability performance continuously.
24th Jun, 2022
Driving operational excellence with SQDECC
SQDECC is an industry-recognized model that enables the operational teams to get a unified view of their efficiency across parameters of Safety, Quality, Delivery, Engagement, Cost, and Compliance (SQDECC).
3rd Dec, 2021
How Organocatalysis discovered by Nobel laureates revolutionised drug development and production in Syngene
11th Oct, 2021
Design of Experiment (DoE) - An efficient tool for process optimization
DoE is achieving increasing acceptance in the pharmaceutical sector as it is being seen as an efficient tool for process optimization, including helping to develop quality products.
31st May, 2021
Things you may not know about continuous flow chemistry
The continuous flow chemistry processes established in the lab can now be readily transferred to the production facilities and scaled up for commercial use without substantially altering reaction conditions.
21st May, 2021
Complimentary techniques for determining Relative response factor of non- isolated impurities
Understanding the concept behind determining UV RRF of non-isolated impurities using High Performance Liquid Chromatography and Nuclear Magnetic Resonance
19th Mar, 2021
Development of degraders: A Medicinal Chemistry perspective
Key considerations for developing protein degraders from a medicinal chemistry perspective regardless of the mechanism of modulation.
4th Mar, 2021
Dedicated R&D Centres - The Next Step In The Pharma Outsourcing Model
Syngene’s Dedicated R&D Centre is a unique business model where we set up a dedicated ring-fenced infrastructure with an exclusive team of scientific talent to support client projects.
22nd Sep, 2020
Syngene’s Supply Chain Management Improves Efficiency
Syngene's SCM team manages more than 1,000 vendors and 20,000 item codes in the SAP ERP system, enabling easy access and order placement.
22nd Sep, 2020

This Website uses Cookies

We use cookies to improve your experience on our site and show you information relevant to your requirements.

To find out more, read our Privacy Policy and Cookies Policy.

To download, Please share your details

To download, Please share your details